Naidoo Analyzes the PACIFIC Regimen for NSCLC
During a Targeted Oncology Case Based Peer Perspective event, Jarushka Naidoo, MBBCh, discussed a case of a 63-year-old patients with non–small cell lung cancer.
Related Articles
Adverse Event Monitoring and Management
Dr. McCloskey discusses the general principles and practices for monitoring and mitigating adverse events, particularly capillary leak syndrome (CLS), in BPDCN patients treated with systemic…
The Future of Breast Cancer Care: Blackwood on Personalized Approaches
In this episode of Targeted Talks, M. Michele Blackwood, MD, FACS, discusses the current landscape of breast cancer treatment and how personalized medicine with genomic…
Lower Radiation Levels Linked to Poorer Tumor Response in Esophageal Cancer
Preoperative low-dose radiation did not deliver response rates comparable with higher doses of radiation among patients undergoing surgical resection for esophageal cancer.
Overview of Bispecific Engagers Administration Program
A description and overview of the bispecific engager administration program at Northside Hospital.
Familiarity Eases Tolerability Challenges With Newer ADCs in Breast Cancer
In this feature, Targeted Oncology spoke to experts in breast cancer treatment on the trends in management of toxicity with the growing drug class of…
FDA Expands Approval for Ide-Cel in Relapsed/Refractory Multiple Myeloma
Idecabtagene vicleucel (ide-cel) demonstrated a 51% reduction in risk of disease progression or death in patients with relapsed or refractory multiple myeloma.
IND Application Submitted to FDA for SynKIR-310 Trial in R/R B-NHL
An investigational new drug application for SynKIR-310’s phase 1 trial targeting relapsed/refractory B-cell non-Hodgkin lymphomas was submitted to the FDA.
FLOT vs CROSS in Resectable GEJ Adenocarcinoma: Which Regimen is Best?
In an interview with Targeted Oncology, Yanghee Woo, MD, discussed some factors to consider when choosing between CROSS and FLOT for gastreoesophageal junction adenocarcinoma treatment.
FDA Approves Trastuzumab Deruxtecan in HER2+ Solid Tumors
Fam-trastuzumab deruxtecan-nxki received accelerated approval from the FDA for adult patients with unresectable or metastatic HER2-positive solid tumors.
The Targeted Pulse: New Approvals, Including Expanded Approvals, GEJ Treatment Debates, and More
The FDA approves T-DXd for HER2+ tumors; SynKIR-310 trials begin, and experts debate FLOT vs. CROSS in GEJ cancer in this week’s recap article.